Portfolio Holdings Detail for ISIN IE000X08RX14
| Stock Name / Fund | iShares MSCI World ESG Enhanced UCITS ETF NZD Hedged (Acc) |
| Issuer | Blackrock |
| Entity holding fund | iShares IV Public Limited Company |
| Entity Type | Umbrella investment company with variable capital and having segregated liability between its funds |
| Entity LEI | 549300ZP07LMR36K1T02 |
| ETF Ticker | EDMNZx(NZD) CXE |
Holdings detail for ALNY
| Stock Name | Alnylam Pharmaceuticals Inc |
| Ticker | ALNY(USD) NASDAQ |
| TYPE | Common Stock |
| Country | USA |
| ISIN | US02043Q1076 |
| LEI | 529900S3ZI14OWRJII50 |
Show aggregate ALNY holdings
News associated with ALNY
- Alnylam Pharmaceuticals (NASDAQ:ALNY) Trading 4% Higher Following Analyst Upgrade
- Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report)’s stock price was up 4% during mid-day trading on Monday after UBS Group raised their price target on the stock from $331.00 to $349.00. UBS Group currently has a buy rating on the stock. Alnylam Pharmaceuticals traded as high as $271.09 and last traded at $269.86. Approximately […] - 2025-05-07 05:24:42
- Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $349.00
- Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) had its price objective lifted by UBS Group from $331.00 to $349.00 in a research report sent to investors on Friday,Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock. Several other equities research analysts have also commented on ALNY. Scotiabank upped their price objective on […] - 2025-05-05 07:25:01
- Alnylam Pharmaceuticals (NASDAQ:ALNY) Cut to “Hold” at StockNews.com
- Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) was downgraded by stock analysts at StockNews.com from a “buy” rating to a “hold” rating in a report released on Wednesday. Other equities analysts have also recently issued research reports about the stock. Sanford C. Bernstein decreased their price objective on shares of Alnylam Pharmaceuticals from $314.00 to […] - 2025-05-02 05:16:49
- These 3 Funds Offer Sky-High Yields of 15% or More and Trade at a Discount
- My definition of a high yield is any yield at least twice the level of the S&P 500's yield. The threshold is currently around 2.56%. An ultra-high yield, in my view, is one that's four times higher than the S&P 500's yield. To reach that lofty level, a yield would need to - 2025-04-30 08:51:00
- StockNews.com Upgrades Alnylam Pharmaceuticals (NASDAQ:ALNY) to “Buy”
- Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) was upgraded by equities research analysts at StockNews.com from a “hold” rating to a “buy” rating in a research note issued to investors on Tuesday. A number of other equities analysts have also weighed in on the stock. Citigroup boosted their price target on shares of Alnylam Pharmaceuticals […] - 2025-04-24 05:16:58
- Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives $315.58 Consensus PT from Brokerages
- Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) have received a consensus rating of “Moderate Buy” from the twenty-six analysts that are presently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating, four have given a hold rating and twenty-one have assigned a buy rating to the […] - 2025-04-18 05:44:49
- Needham & Company LLC Reaffirms “Buy” Rating for Alnylam Pharmaceuticals (NASDAQ:ALNY)
- Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report)‘s stock had its “buy” rating reaffirmed by stock analysts at Needham & Company LLC in a research note issued to investors on Wednesday,Benzinga reports. They currently have a $320.00 price target on the biopharmaceutical company’s stock. Needham & Company LLC’s price target would indicate a potential upside of […] - 2025-04-11 06:12:48
- Corebridge Financial Inc. Has $520,000 Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
- Corebridge Financial Inc. lessened its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 2.2% during the 4th quarter, HoldingsChannel reports. The fund owned 2,209 shares of the biopharmaceutical company’s stock after selling 50 shares during the quarter. Corebridge Financial Inc.’s holdings in Alnylam Pharmaceuticals were worth $520,000 at the end of […] - 2025-04-09 07:44:49
- Top Analyst Reports for Broadcom, UnitedHealth & Toyota Motor
- Today's Research Daily features new research reports on 16 major stocks, including Broadcom Inc. (AVGO), UnitedHealth Group Incorporated (UNH) and Toyota Motor Corporation (TM), as well as a micro-cap stock Perma-Pipe International Holdings, Inc. (PPIH). - 2025-04-04 20:54:00
- Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $345.00
- Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) had its target price increased by Stifel Nicolaus from $300.00 to $345.00 in a report released on Monday,Benzinga reports. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Stifel Nicolaus’ price objective suggests a potential upside of 34.89% from the company’s previous close. A number […] - 2025-04-02 05:27:03
- Alnylam Pharmaceuticals (NASDAQ:ALNY) Given New $342.00 Price Target at Scotiabank
- Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) had its target price upped by research analysts at Scotiabank from $338.00 to $342.00 in a report issued on Monday,Benzinga reports. The firm presently has a “sector outperform” rating on the biopharmaceutical company’s stock. Scotiabank’s target price would indicate a potential upside of 33.72% from the company’s previous […] - 2025-04-02 05:26:50
- Incyte Stock: Is INCY Outperforming the Health Care Sector?
- Incyte has outperformed the health care sector over the past year, and analysts are moderately optimistic about the stock’s prospects. - 2025-04-01 15:55:45
- Stocks Recover Early Losses and Close Higher as Magnificent Seven Stocks Rebound
- The S&P 500 Index ($SPX ) (SPY ) Friday closed up +0.08%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.08%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.39%. June E-mini S&P futures (ESM25 ) are up +0.08%, and June E-mini Nasdaq futures... - 2025-03-24 12:01:12
- Natixis Advisors LLC Boosts Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
- Natixis Advisors LLC grew its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 4.5% during the 4th quarter, HoldingsChannel reports. The fund owned 10,453 shares of the biopharmaceutical company’s stock after acquiring an additional 451 shares during the quarter. Natixis Advisors LLC’s holdings in Alnylam Pharmaceuticals were worth $2,460,000 at the […] - 2025-03-24 08:44:53
- Needham & Company LLC Reaffirms “Buy” Rating for Alnylam Pharmaceuticals (NASDAQ:ALNY)
- Needham & Company LLC reiterated their buy rating on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) in a research note released on Friday,Benzinga reports. The brokerage currently has a $320.00 price target on the biopharmaceutical company’s stock. A number of other research firms have also recently issued reports on ALNY. William Blair reissued an […] - 2025-03-24 07:00:43
- Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Price Expected to Rise, Citigroup Analyst Says
- Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) had its price objective upped by Citigroup from $338.00 to $351.00 in a research note released on Friday,Benzinga reports. The firm currently has a buy rating on the biopharmaceutical company’s stock. ALNY has been the topic of several other research reports. William Blair reiterated an “outperform” rating on shares […] - 2025-03-24 06:24:53
- Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $390.00
- Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) had its price target increased by Canaccord Genuity Group from $385.00 to $390.00 in a report issued on Friday,Benzinga reports. The brokerage currently has a buy rating on the biopharmaceutical company’s stock. Several other equities research analysts have also issued reports on the company. Bank of America raised their […] - 2025-03-24 05:48:46
- Royal Bank of Canada Increases Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target to $330.00
- Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) had its price objective lifted by Royal Bank of Canada from $310.00 to $330.00 in a research report released on Friday morning,Benzinga reports. They currently have an outperform rating on the biopharmaceutical company’s stock. ALNY has been the subject of several other reports. StockNews.com downgraded shares of Alnylam Pharmaceuticals […] - 2025-03-24 05:48:44
- Stocks Pare Losses as S&P 500 Looks for Weekly Win
- The S&P 500 Index ($SPX ) (SPY ) today is down -0.31%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.20%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.18%. June E-mini S&P futures (ESM25 ) are down -0.28%, and June E-mini Nasdaq futures... - 2025-03-21 23:21:08
- Weak Corporate Earnings Results Weigh on Stocks
- The S&P 500 Index ($SPX ) (SPY ) today is down -0.81%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.95%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.97%. March E-mini S&P futures (ESH25 ) are down -0.84%, and March E-mini Nasdaq futures... - 2025-03-21 20:55:40
- Stocks Fall on Disappointing Corporate Earnings and Economic Worries
- The S&P 500 Index ($SPX ) (SPY ) today is down -0.54%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.62%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.53%. June E-mini S&P futures (ESM25 ) are down -0.50%, and June E-mini Nasdaq futures... - 2025-03-21 18:18:20
- Friday's ETF Movers: XBI, COPX
- In trading on Friday, the SPDR S&P Biotech ETF is outperforming other ETFs, up about 0.7% on the day. Components of that ETF showing particular strength include shares of Alnylam Pharmaceuticals, up about 13.1% and shares of Cytokinetics, up about 7.8% on the day.
And unde - 2025-03-21 16:11:45
- Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Acquired by Atria Investments Inc
- Atria Investments Inc increased its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 5.3% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 3,311 shares of the biopharmaceutical company’s stock after acquiring an additional 166 shares during the quarter. Atria Investments Inc’s […] - 2025-03-14 09:52:58
- Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Bought by Proficio Capital Partners LLC
- Proficio Capital Partners LLC lifted its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 25,929.6% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 193,660 shares of the biopharmaceutical company’s stock after acquiring an additional 192,916 shares during the period. Alnylam Pharmaceuticals makes up approximately 0.6% of Proficio Capital Partners […] - 2025-03-14 09:05:23
- USMV's Underlying Holdings Could Mean 11% Gain Potential
- Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-03-10 11:43:47
- Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Position Lessened by Principal Financial Group Inc.
- Principal Financial Group Inc. lowered its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 2.2% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 10,378 shares of the biopharmaceutical company’s stock after selling 230 shares during the quarter. Principal Financial Group Inc.’s holdings […] - 2025-03-06 10:01:07
- New York Life Investment Management LLC Boosts Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
- New York Life Investment Management LLC increased its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 6.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,384 shares of the biopharmaceutical company’s stock after buying an additional 153 shares during the period. […] - 2025-03-05 10:04:47
- Brokerages Set Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) PT at $299.48
- Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) have received a consensus rating of “Moderate Buy” from the twenty-five research firms that are currently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and nineteen have issued a buy […] - 2025-02-27 06:53:09
- Sanctuary Advisors LLC Boosts Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
- Sanctuary Advisors LLC boosted its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 7.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 4,915 shares of the biopharmaceutical company’s stock after purchasing an additional 357 shares during the period. Sanctuary […] - 2025-02-26 08:50:51
- Venturi Wealth Management LLC Buys 248 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
- Venturi Wealth Management LLC increased its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 6,200.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 252 shares of the biopharmaceutical company’s stock after acquiring an additional 248 shares during the […] - 2025-02-25 09:02:56
iShares MSCI World ESG Enhanced UCITS ETF NZD Hedged (Acc) ALNY holdings
| Date | Number of ALNY Shares Held | Base Market Value of ALNY Shares | Local Market Value of ALNY Shares | Change in ALNY Shares Held | Change in ALNY Base Value | Current Price per ALNY Share Held | Previous Price per ALNY Share Held |
|---|
| 2024-11-08 (Friday) | 2,341 | USD 649,464 | USD 649,464 | 0 | USD 12,197 | USD 277.43 | USD 272.22 |
| 2024-11-07 (Thursday) | 2,341 | USD 637,267 | USD 637,267 | 0 | USD -1,849 | USD 272.22 | USD 273.01 |
| 2024-11-06 (Wednesday) | 2,341 | USD 639,116 | USD 639,116 | 0 | USD 18,072 | USD 273.01 | USD 265.29 |
| 2024-11-05 (Tuesday) | 2,341 | USD 621,044 | USD 621,044 | 0 | USD -10,909 | USD 265.29 | USD 269.95 |
| 2024-11-04 (Monday) | 2,341 | USD 631,953 | USD 631,953 | 0 | USD -9,270 | USD 269.95 | USD 273.91 |
| 2024-11-01 (Friday) | 2,341 | USD 641,223 | USD 641,223 | -32 | USD 8,605 | USD 273.91 | USD 266.59 |
| 2024-10-31 (Thursday) | 2,373 | USD 632,618 | USD 632,618 | 0 | USD -35,358 | USD 266.59 | USD 281.49 |
| 2024-10-30 (Wednesday) | 2,373 | USD 667,976 | USD 667,976 | 0 | USD -7,593 | USD 281.49 | USD 284.69 |
| 2024-10-29 (Tuesday) | 2,373 | USD 675,569 | USD 675,569 | 0 | USD -5,268 | USD 284.69 | USD 286.91 |
| 2024-10-28 (Monday) | 2,373 | USD 680,837 | USD 680,837 | 0 | USD 4,864 | USD 286.91 | USD 284.86 |
| 2024-10-25 (Friday) | 2,373 | USD 675,973 | USD 675,973 | 0 | USD -20,953 | USD 284.86 | USD 293.69 |
| 2024-10-24 (Thursday) | 2,373 | USD 696,926 | USD 696,926 | 0 | USD -2,801 | USD 293.69 | USD 294.87 |
| 2024-10-23 (Wednesday) | 2,373 | USD 699,727 | USD 699,727 | 0 | USD -3,820 | USD 294.87 | USD 296.48 |
| 2024-10-22 (Tuesday) | 2,373 | USD 703,547 | USD 703,547 | 0 | USD 10,607 | USD 296.48 | USD 292.01 |
| 2024-10-21 (Monday) | 2,373 | USD 692,940 | USD 692,940 | 0 | USD -9,302 | USD 292.01 | USD 295.93 |
| 2024-10-18 (Friday) | 2,373 | USD 702,242 | USD 702,242 | | | | |
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdingsShare Trades of ALNY by Blackrock for IE000X08RX14
Show aggregate share trades of ALNY| Date | Action | Quantity | Market High | Market Low | Likely Trade Price | Likely Trade Value (Profit/Loss) | Average Price previous trades |
|---|
| 2024-11-01 | SELL | -32 | | | 273.910* | | 286.84 Profit of 9,179 on sale |
Market high and low price is on the date. * (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection
The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close
Shorting History of ALNY
| Date | Shorted Volume | Short Exempt Volume | Total Shares Traded | % Shorted |
|---|
| 2025-05-08 | 382,581 | 1,581 | 899,416 | 42.5% |
| 2025-05-07 | 131,446 | 2,828 | 218,311 | 60.2% |
| 2025-05-06 | 517,911 | 7,413 | 716,637 | 72.3% |
| 2025-05-05 | 304,356 | 3,848 | 527,589 | 57.7% |
| 2025-05-02 | 136,007 | 3,773 | 208,069 | 65.4% |
| 2025-05-01 | 363,746 | 490 | 677,635 | 53.7% |
| 2025-04-30 | 237,684 | 4,832 | 415,338 | 57.2% |
| 2025-04-29 | 198,389 | 5,983 | 331,267 | 59.9% |
| 2025-04-28 | 136,842 | 1,137 | 229,407 | 59.7% |
| 2025-04-25 | 222,776 | 1,993 | 348,407 | 63.9% |
| 2025-04-24 | 115,163 | 1,767 | 238,257 | 48.3% |
| 2025-04-23 | 208,801 | 464 | 350,364 | 59.6% |
| 2025-04-22 | 136,015 | 231 | 332,849 | 40.9% |
| 2025-04-21 | 209,611 | 603 | 306,742 | 68.3% |
| 2025-04-17 | 165,451 | 74 | 243,558 | 67.9% |
| 2025-04-16 | 270,294 | 3,357 | 446,370 | 60.6% |
| 2025-04-15 | 238,076 | 403 | 494,216 | 48.2% |
| 2025-04-14 | 157,148 | 3,912 | 316,108 | 49.7% |
| 2025-04-11 | 486,937 | 14,123 | 679,583 | 71.7% |
| 2025-04-10 | 500,597 | 2,591 | 780,526 | 64.1% |
| 2025-04-09 | 557,115 | 11,336 | 965,760 | 57.7% |
| 2025-04-08 | 214,094 | 1,301 | 383,794 | 55.8% |
| 2025-04-07 | 358,679 | 32,038 | 613,763 | 58.4% |
| 2025-04-04 | 431,556 | 1,025 | 725,195 | 59.5% |
| 2025-04-03 | 342,351 | 477 | 430,262 | 79.6% |
| 2025-04-02 | 233,896 | 1,506 | 378,459 | 61.8% |
| 2025-04-01 | 183,265 | 8,200 | 380,248 | 48.2% |
| 2025-03-31 | 210,777 | 4,770 | 352,191 | 59.8% |
| 2025-03-28 | 133,425 | 181 | 279,765 | 47.7% |
| 2025-03-27 | 203,567 | 6,557 | 375,583 | 54.2% |
| 2025-03-26 | 285,175 | 1,249 | 426,226 | 66.9% |
| 2025-03-25 | 281,688 | 10,979 | 412,440 | 68.3% |
| 2025-03-24 | 482,334 | 25,397 | 826,008 | 58.4% |
| 2025-03-21 | 836,066 | 28,323 | 1,366,248 | 61.2% |
| 2025-03-20 | 192,017 | 151 | 422,450 | 45.5% |
| 2025-03-19 | 179,759 | 63 | 447,452 | 40.2% |
| 2025-03-18 | 180,640 | 478 | 331,282 | 54.5% |
| 2025-03-17 | 121,129 | 153 | 260,376 | 46.5% |
| 2025-03-14 | 105,130 | 8,747 | 179,061 | 58.7% |
| 2025-03-13 | 70,794 | 138 | 132,716 | 53.3% |
| 2025-03-12 | 124,070 | 84 | 268,287 | 46.2% |
| 2025-03-11 | 137,713 | 2,010 | 247,323 | 55.7% |
| 2025-03-10 | 77,724 | 66 | 208,123 | 37.3% |
| 2025-03-07 | 116,885 | 207 | 186,950 | 62.5% |
| 2025-03-06 | 92,455 | 1,888 | 194,307 | 47.6% |
The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.
Back to Listing
Disclaimer
All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.